A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment

Study Overview
=================
Brief Summary
-----------------
This is a multicenter retrospective study in good prognosis Chinese patients. Data will be collected from infertile women who underwent first in vitro fertilization (IVF)/intra cytoplasmic sperm injection (ICSI) using a Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide) protocol at about 4 IVF centers to investigate the factors associated with clinical pregnancy rate. The definition of the good prognosis subjects is, age not more than 35 years old, Baseline serum Follicle-stimulating hormone (FSH) level no more than 10 milliinternational units (mIU)/milliliter (ml), Body mass index (BMI) not more than 30 kilogram per meter square (kg/m^2), previously underwent no more than 3 IVF/ICSI cycles, and the total dose of Gonadotropin used no more than 2500 IU in current cycle. No intervention(s) will be administered on the subjects. Data required to investigate the factors associated with the pregnancy outcome of GnRH antagonist IVF cycle will be collected from the subjects' medical records into database through electronic data capture system and analyzed.

Official Title
-----------------
A Retrospective Study in Chinese Good Prognosis Patients Undergoing ART Treatment to Investigate the Factors Associated With the Pregnancy Outcome of GnRH Antagonist IVF/ICSI Cycles

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: No Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infertile women who underwent the first GnRH antagonist IVF/ICSI-ET (Embryo Transfer) cycle with an available ART outcome Used Cetrotide in a fixed or flexible antagonist protocol Age not more than 35 years old Baseline serum Follicle-stimulating hormone (FSH) level not more than 10 milliinternational unit per milliliter (mIU/ml) Body mass index (BMI) not more than 30 kilogram per meter square (kg/m^2) Normal uterine cavity Exclusion Criteria: Previously underwent 3 or more IVF/ICSI cycles The total dose of Gonadotropin used was more than 2500 IU in current cycle Administration of daily 0.125 milligram (mg) Cetrotide Received an agonist trigger Use of clomiphene citrate or letrozole during cycles Presence of endometriosis Grade 3 to 4, confirmed or suspected Presence of uni-or-bilateral hydrosalpinx Known history of recurrent miscarriages

Ages Eligible for Study
-----------------
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cetrotide<br>This study will retrospectively collect the data from the subjects who had been treated with 0.25 milligram (mg) of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available assisted reproductive technology (ART) outcome. | Drug: No Intervention<br>* This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical Pregnancy Rate | Number of clinical pregnancies expressed per 100 initiated cycles, aspiration cycles, and embryo transfer cycles. Initiated cycle: an assisted reproductive technology (ART) cycle in which the woman receives specific medication for ovarian stimulation, or monitoring in the case of natural cycles, with the intention to treat, irrespective of whether or not follicular aspiration is attempted. Aspiration cycle Initiated ART cycle in which one or more follicles are punctured and aspirated irrespective of whether or not oocytes are retrieved. Embryo transfer cycle: an ART cycle in which one or more embryos are transferred into the uterus or fallopian tube. | 5 months | 
| Implantation Rate | Implantation rate = (The number of gestational sacs observed divided by the number of embryos transferred)*100 | 5 months | 
| Ongoing Pregnancy Rate | Ongoing pregnancy rate per embryo transfer cycles = (Number of Ongoing pregnancy/Number of embryo transfer cycles)*100 and ongoing pregnancy rate per initiated cycles = (Number of Ongoing pregnancy/Number of initiated cycles) *100 | 5 months | 
| Incidence and Severity of Ovarian Hyperstimulation Syndrome (OHSS) |  | 5 months | 
| Cycle Cancelled Rate | Cycle cancelled rate = (Number of subjects with terminated in vitro fertilization (IVF) or intra cytoplasmic sperm injection (ICSI) treatment/Number of initiated cycles)*100 | 5 months | 
| Early Miscarriage Rate | (Number of Early miscarriages/Number of clinical pregnancies)*100 | 5 months | 
| Live Birth Rate | Number of live births expressed per 100 initiated cycles, aspiration cycles or embryo transfer cycles. When delivery rates are given, the denominator (initiated, aspirated, or embryo transfer cycles) will be specified | 5 months | 
| Type of Gonadoptropin |  | 5 months | 
| Brand of Gonadotropin |  | 5 months | 
| Total Dose of Gonadotropin |  | 5 months | 
| Duration of Gonadotropin Administration |  | 5 months | 
| Cetrotide Start Day |  | up to 5 months | 
| Leading Follicle Size on the Day of Starting Cetrotide |  | on the day of starting Cetrotide (up to 5 months) | 
| Serum Luteinizing Hormone (LH) Level on the Day of Starting Cetrotide |  | on the day of starting Cetrotide (up to 5 months) | 
| Serum Estradiol (E2) Level on the Day of Starting Cetrotide |  | on the day of starting Cetrotide (up to 5 months) | 
| Serum Luteinizing Hormone (LH), Level on the Day of Human Chorionic Gonadotropin (hCG) Triggering |  | 5 months | 
| Serum Estradiol (E2) Level on the Day of Human Chorionic Gonadotropin (hCG) Triggering |  | on the day of hCG triggering (up to 5 months) | 
| Progesterone Level on the Day of Human Chorionic Gonadotropin (hCG) Triggering |  | on the day of hCG triggering (up to 5 months) | 
| Number of Follicles With Size 14 milimeter (mm) or More on the Day of Human Chorionic Gonadotropin (hCG) Triggering |  | on the day of hCG triggering (up to 5 months) | 
| Endometrial Thickness on the Day of Human Chorionic Gonadotropin (hCG) Triggering |  | on the day of hCG triggering (up to 5 months) | 
| Serum Luteinizing Hormone (LH) Level on the Day of Observed Premature Luteinizing Hormone (LH) Rise | Subjects will be characterized as having a premature LH rise if any measured LH value during follicular recruitment will more than (>) 10 International Units Per Litre (IU/L) up to and including the day of the trigger | on the day of observed premature LH rise (up to 5 months) | 
| Serum Estradiol (E2) Level on the Day of Observed Premature Luteinizing Hormone (LH) Rise | Subjects will be characterized as having a premature LH rise if any measured LH value during follicular recruitment will more than (>) 10 International Units Per Litre (IU/L) up to and including the day of the trigger | on the day of observed premature LH rise (up to 5 months) | 
| Serum Progesterone Level on the Day of Observed Premature Luteinizing Hormone (LH) Rise | Subjects will be characterized as having a premature LH rise if any measured LH value during follicular recruitment will more than (>) 10 International Units Per Litre (IU/L) up to and including the day of the trigger | on the day of observed premature LH rise (up to 5 months) | 
| Number of Follicles With Size 14 mm or More on the Day of Observed Premature Luteinizing Hormone (LH) Rise | Subjects will be characterized as having a premature LH rise if any measured LH value during follicular recruitment will more than (>) 10 International Units Per Litre (IU/L) up to and including the day of the trigger | on the day of observed premature LH rise (up to 5 months) | 
| Endometrial Thickness on the Day of Observed Premature Luteinizing Hormone (LH) Rise | Subjects will be characterized as having a premature LH rise if any measured LH value during follicular recruitment will more than (>) 10 International Units Per Litre (IU/L) up to and including the day of the trigger | on the day of observed premature LH rise (up to 5 months) | 
| Serum Progesterone Level on the Day of Observed Premature Progesterone Rise | Premature progesterone rise: A rise in serum progesterone levels above 1.5 nanogram/milliliter (ng/ml) towards the end of the follicular phase up to and including the day of the trigger | on the day of observed premature progesterone rise (up to 5 months) | 
| Number of Oocytes Obtained |  | 5 months | 
| Number of Mature Metaphase II Oocytes Obtained |  | 5 months | 
| Fertilization Rate |  | 5 months | 
| Total Number of Embryos on Day 3/Blastocysts on Day 5 |  | Day 3 and Day 5 | 
| Number of Cryopreservation Embryos/Blastocysts on Day 3 or Day 5 |  | Day 3, Day 5 | 
| Number of Embryos/Blastocysts Transferred on Day 3 or Day 5 |  | Day 3, Day 5 | 
| Number of Good Quality Embryos/Blastocysts Transferred |  | up to 5 months | 
| Age |  | Baseline | 
| Duration of Infertility |  | Baseline | 
| Type of Infertility |  | Baseline | 
| Body Mass Index (BMI) |  | Baseline | 
| Smoking Status |  | Baseline | 
| Cause of Infertility |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infertility, Cetrotide, Assisted reproductive technology (ART)